Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Haley Swanson

Nurse Practitioner, Primary Care Virginia Beach, VA Nurse Practitioner

NPI 1972254118 CMS profile 11310624

4445 Corporation Ln Ste 120, Virginia Beach, VA 23462

Open in the dashboard

General payments

$4,299

222 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Haley Swanson of Virginia Beach, VA is reported in the CMS Open Payments database as having received $4,299 across 222 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,049 53
2024 General $1,272 59
2023 General $1,390 77
2022 General $587 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Haley Swanson
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Haley Swanson were reported at $1,049. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Haley Swanson Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $137 $39–$445 $132
2022 $587 $139 $44–$421 $149
2023 $1,390 $163 $53–$481 $160
2024 $1,272 $176 $54–$511 $164
2025 $1,049 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $748 43 payments
  2. AstraZeneca Pharmaceuticals LP $743 29 payments
  3. AbbVie, Inc. $731 45 payments
  4. Pfizer Inc. $399 22 payments
  5. Lilly USA, LLC $359 22 payments
  6. Otsuka America Pharmaceutical, Inc. $303 14 payments
  7. Astellas Pharma US Inc $203 7 payments
  8. GlaxoSmithKline, LLC. $176 7 payments
  9. Currax Pharmaceuticals LLC $98 6 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $65 3 payments
  11. Other $473 24 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,174 220 payments
  2. Education $125 2 payments
Products named General payments · program years 2022–2025
  1. Ozempic $581 33 payments
  2. RYBELSUS $566 32 payments
  3. FARXIGA $361 13 payments
  4. VRAYLAR $306 20 payments
  5. REXULTI $303 14 payments
  6. QULIPTA $299 16 payments
  7. UBRELVY $299 18 payments
  8. AIRSUPRA $292 6 payments
  9. BREZTRI $273 11 payments
  10. MOUNJARO $246 15 payments
  11. Other $2,301 132 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 78 drugs

Part D claims

2,911

Median for Nurse Practitioner: 389

Drug cost

$260,103

Median for Nurse Practitioner: $21,885

Branded share of claims

15.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 64 $58,267
Ozempic Semaglutide Brand 37 $53,461
Jardiance Empagliflozin Brand 26 $34,191
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 17 $23,518
Eliquis Apixaban Brand 21 $18,636
Trulicity Dulaglutide Brand 15 $15,800
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 14 $10,908
Xarelto Rivaroxaban Brand 12 $8,532
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 11 $5,364
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 17 $4,059

The 10 drugs with the highest cost, of 78 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$69,159

Of which drugs: $9,817

Medicare patients

286

Average age 75

Services billed

1,096

163 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Osteoporosis 44%
Diabetes 39%
Arthritis 37%
Chronic kidney disease 27%
Ischemic heart disease 17%
COPD 17%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 61 61 $4,716
Pcv20 vaccine im 90677 Office 16 16 $4,646
Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older 90715 Office 11 11 $272

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $195
$195 — —
Ozempic
  • Novo Nordisk Inc $109
$109 37 —
VRAYLAR
  • AbbVie, Inc. $98
$98 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $97
$97 — —
RYBELSUS
  • Novo Nordisk Inc $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

222 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record